Skip to main content
. 2021 May 11;16(5):1165–1181. doi: 10.1016/j.stemcr.2021.04.001

Figure 4.

Figure 4

CD45+ CECs from the peripheral blood of COVID-19 patients and human bone marrow exhibit the highest intensity of ACE2 expression compared with other immune cells

(A) Plots showing the expression of ACE2 on CD45 CECs versus CD45+ CECs from PBMCs from a COVID-19 patient.

(B) Percentage of ACE2 surface expression on total CECs and immune cell lineages in PBMCs from a COVID-19 patient.

(C) Cumulative data of the percentage of ACE2 expressing cells among different immune cell lineages and CECs in PBMCs from COVID-19 patients.

(D and E) (D) Representative plots and (E) cumulative data of the intensity of ACE2 expression in CD45+ CECs, CD45 CECs, and immune cell lineages measured by mean fluorescence intensity (MFI) in PBMCs from COVID-19 patients.

(F) Representative plots of the percentage of ACEs expression in CD45, CD45lo, and CD45hiCECs in PBMCs from COVID-19 patients.

(G) Plot showing the intensity of ACE2 expression in CD45hi, CD45lo, and CD45 CECs compared with isotype control in PBMCs from COVID-19 patients.

(H) Plots showing the expression of ACE2 on CD19 B cells, CD3 T cells, CD16CD56 NK cells, CD14 monocytes, and CECs compared with the isotype control antibody in the bone marrow aspirates of a healthy adult.

(I) Representative plots of the percentage of ACEs expression in CD45, CD45lo, and CD45hiCECs of the bone marrow.

(J) Histogram plot of the intensity of ACE2 expression in CD45hi, CD45lo, and CD45 CECs of the bone marrow compared with isotype control. Each point represents data from one patient. Bar, mean ± 1 standard error.